RE: RE: NR - When?I seem to recall that Phase 2b cost was in the $5 million range - but I'm really guessing.
Phase 3 would run 3-4X that amount, assuming that the design will mirror 2b - which is a reasonable assumption if efficacy holds and side effects/adverse reaction remain a non issue. They may only need to extend 2b to a larger population base to confirm statistical significance.